MXPA03009506A - USO DE COMPUESTOS ELIMINADORES DE RADICALES PARA EL TRATAMIENTO Y PREVENCIoN DE TRASTORNOS DE LA MICRO-CIRCULACION DEPENDIENTES DE NO. - Google Patents

USO DE COMPUESTOS ELIMINADORES DE RADICALES PARA EL TRATAMIENTO Y PREVENCIoN DE TRASTORNOS DE LA MICRO-CIRCULACION DEPENDIENTES DE NO.

Info

Publication number
MXPA03009506A
MXPA03009506A MXPA03009506A MXPA03009506A MXPA03009506A MX PA03009506 A MXPA03009506 A MX PA03009506A MX PA03009506 A MXPA03009506 A MX PA03009506A MX PA03009506 A MXPA03009506 A MX PA03009506A MX PA03009506 A MXPA03009506 A MX PA03009506A
Authority
MX
Mexico
Prior art keywords
prevention
treatment
radical scavenging
scavenging compounds
microcirculation disorders
Prior art date
Application number
MXPA03009506A
Other languages
English (en)
Inventor
Wolfgang Eisert
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of MXPA03009506A publication Critical patent/MXPA03009506A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MXPA03009506A 2001-04-20 2002-04-13 USO DE COMPUESTOS ELIMINADORES DE RADICALES PARA EL TRATAMIENTO Y PREVENCIoN DE TRASTORNOS DE LA MICRO-CIRCULACION DEPENDIENTES DE NO. MXPA03009506A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10119680A DE10119680A1 (de) 2001-04-20 2001-04-20 Verwendung von Radikalfänger-Verbindungen zur Behandlung und Verhinderung von no-abhängigen Störungen der Mikrozirkulation
PCT/EP2002/004129 WO2002085368A2 (en) 2001-04-20 2002-04-13 Use of radical scavenging compounds for treatment and prevention of no-dependent microcirculation disorders

Publications (1)

Publication Number Publication Date
MXPA03009506A true MXPA03009506A (es) 2004-02-12

Family

ID=7682292

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03009506A MXPA03009506A (es) 2001-04-20 2002-04-13 USO DE COMPUESTOS ELIMINADORES DE RADICALES PARA EL TRATAMIENTO Y PREVENCIoN DE TRASTORNOS DE LA MICRO-CIRCULACION DEPENDIENTES DE NO.

Country Status (10)

Country Link
EP (1) EP1389112A2 (es)
JP (1) JP2004525979A (es)
AU (1) AU2002338396B2 (es)
CA (1) CA2444370A1 (es)
DE (1) DE10119680A1 (es)
HU (1) HUP0303754A3 (es)
IL (1) IL158091A0 (es)
MX (1) MXPA03009506A (es)
NZ (1) NZ529115A (es)
WO (1) WO2002085368A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1846058T3 (da) * 2005-02-11 2009-11-23 Nolabs Ab Indretning, fremgangsmåde og anvendelse til behandling af neuropati med nitrogenoxid
MD4341C1 (ro) * 2013-11-21 2015-11-30 Ион МЕРЕУЦЭ Sirop pentru tratamentul stărilor precanceroase gastrice
JP6925272B2 (ja) * 2015-01-28 2021-08-25 リアルイン ライフ サイエンス リミテッド ＰＰＡＲγ発現および核転座を促進する化合物およびそれの治療的使用
CN113244395A (zh) * 2020-02-10 2021-08-13 广州市妇女儿童医疗中心 纤维化疾病机制及其治疗药物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1711892A1 (ru) * 1989-01-06 1992-02-15 Московский медицинский стоматологический институт им.Н.А.Семашко Способ лечени диабетической ангиопатии
SU1711894A1 (ru) * 1989-08-08 1992-02-15 Детская Клиническая Больница N1 Способ лечени декомпенсированных форм стенозирующего ларинготрахеита у детей
IT1239064B (it) * 1990-05-14 1993-09-20 Fidia Spa Uso terapeutico del dipiridamolo
US5270047A (en) * 1991-11-21 1993-12-14 Kauffman Raymond F Local delivery of dipyridamole for the treatment of proliferative diseases
AU7397094A (en) * 1993-08-30 1995-03-22 Merck & Co., Inc. Prevention and treatment of alzheimer's disease
US5639482A (en) * 1993-11-10 1997-06-17 Crary; Ely J. Composition for control and prevention of diabetic retinopathy
WO2000067737A2 (en) * 1999-05-07 2000-11-16 The Brigham And Women's Hospital, Inc. USE OF HMGCoA REDUCTASE INHIBITORS IN THE PREVENTION OF DISEASES WHOSE PATHOGENESIS IS DEPENDENT ON NEOVASCULARIZATION
EP1093814A1 (en) * 1999-10-22 2001-04-25 Boehringer Ingelheim Pharma KG Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders

Also Published As

Publication number Publication date
DE10119680A1 (de) 2002-11-14
JP2004525979A (ja) 2004-08-26
IL158091A0 (en) 2004-03-28
WO2002085368A3 (en) 2003-02-20
HUP0303754A2 (hu) 2004-03-01
EP1389112A2 (en) 2004-02-18
WO2002085368A2 (en) 2002-10-31
NZ529115A (en) 2005-08-26
HUP0303754A3 (en) 2006-02-28
AU2002338396B2 (en) 2007-10-18
CA2444370A1 (en) 2002-10-31

Similar Documents

Publication Publication Date Title
AU2003290548A8 (en) Prevention and treatment of synucleinopathic disease
HK1068551A1 (en) Substituted benzimidazole compounds and their use for the treatment of cancer
AU5714601A (en) Methods for prevention and treatment of gastrointestinal disorders
HK1086488A1 (en) Compound and use thereof for the treatment of cancer
EP1392292A4 (en) PYRANOINDAZOLES AND THEIR USE IN GLAUCOMA TREATMENT
PL372928A1 (en) Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
HUP0400005A3 (en) Use of osteopontin for the treatment and/or prevention of neurologic diseases
HUP0401808A3 (en) Dosage forms, devices and methods of treatment
ZA200208228B (en) Use of il-18 inhibitors for the treatment and/or prevention of athesclerosis
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
EP1553951A4 (en) COMPOSITIONS CONTAINING A JNK INHIBITOR FOR TREATING, PREVENTING, MANAGING AND / OR MODIFYING PAIN, AND METHODS OF USE THEREOF
HUP0303236A3 (en) Carbamate compounds for use in the treatment of pain
HRP20030609A2 (en) Use of il-18 inhibitors for the treatment and/or prevention of heart disease
GB0105613D0 (en) Pharmaceutically effective compounds and their use
IL161748A0 (en) New use for the treatment of gastroesophageal reflux
MXPA03009506A (es) USO DE COMPUESTOS ELIMINADORES DE RADICALES PARA EL TRATAMIENTO Y PREVENCIoN DE TRASTORNOS DE LA MICRO-CIRCULACION DEPENDIENTES DE NO.
HUP0302738A3 (en) Use of sarp-1 for the treatment and/or prevention of scleroderma
EE200300057A (et) Koostis vähi profülaktikaks ja raviks
IL160551A0 (en) Plaster for the treatment of dysfunctions and disorders of nails
AU2003287513A8 (en) Inhibitors of beta-secretase, and their use for the prevention or treatment of alzheimer's disease or mild cognitive impairment
FI20021948A0 (fi) Menetelmiä ja koostumuksia sileän lihassolun uudiskasvun hoitoon ja ennaltaehkäisyyn
EP1372630A4 (en) AGENT FOR THE TREATMENT OF THE HYPERACTIVE BLADDER
SI1392292T1 (sl) Piranoindazoli in njihova uporaba pri zdravljenjuglavkoma
GB0219811D0 (en) Treatment of excreta
IT1306143B1 (it) Composizione per la prevenzione ed il trattamento delle alterazionimentali e comportamentali.

Legal Events

Date Code Title Description
FG Grant or registration